Table 4.

Matched odds ratios associated with antibody titers in class II alleles and haplotypes^c

Allele/ haplotypea	Anti-GAD		Anti-IA2
	P	aOR (95% CI)b	P	aOR (95% CI)
DRB1*030101	<0.001	5.23 (2.21–12.40)	0.582	1.37 (0.60–3.09)
DRB1*040101	0.478	1.52 (0.61–3.78)	0.100	2.31 (0.95–5.52)
DRB1*070101	0.016	0.30 (0.11–0.82)	0.424	0.56 (0.21–1.70)
DRB1*110101	<0.001	0.75 (0.66–0.86)	0.269	0.34 (0.09–1.67)
DQB1*030101	0.006	0.21 (0.07–0.67)	0.424	0.56 (0.21–1.70)
DRB1*060101	0.070	0.39 (0.14–1.06)	0.144	0.33 (0.11–1.27)
DRB1*030101/DQB1*0201	<0.001	15.76 (5.83–42.57)	0.151	1.99 (0.87–4.44)
DRB1*040101/DQB1*0302	0.102	2.45 (0.86–7.02)	<0.001	5.60 (2.01–14.33)
DRB1*070101/DQB1*0201	0.006	0.21 (0.07–0.67)	0.168	0.28 (0.08–1.40)
DRB1*110101/DQB1*030101	<0.001	0.75 (0.66–0.86)	0.380	0.54 (0.20–1.63)

^aOnly alleles and haplotypes significantly associated with altered risk of T1DM in Tunisians (7).

^bThe reference group was patients negative for the specific allele or haplotype. aOR, adjusted odds ratio, controlled for gender, age of onset, and fasting glucose.

^cBoldface indicates statistical significance.